In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells.
In Vivo MRI Tracking of Tumor Vaccination and Antigen Presentation by Dendritic Cells.
复制标题
DOI：
10.1007/s11307-021-01647-4
复制
发表时间：
2022-04
影响因子：
3.1
通讯作者：
Shakeri-Zadeh A
中科院分区：
文献类型：
--
作者：
Bulte JWM;Shakeri-Zadeh A
大约25年前，使用肿瘤抗原引发的树突状细胞（DC）的癌症疫苗被引入临床，但总体结果并没有达到最初的预期。除了免疫应答的复杂性之外，还有许多因素决定DC治疗的疗效。这些包括在靶组织部位准确施用DC而没有不希望的细胞分散/回流，足够数量的肿瘤抗原致敏的DC归巢到淋巴结（LN），以及适当的免疫佐剂施用时机。为了解决这些不确定性，质子（1H）和氟（19 F）磁共振成像（MRI）跟踪离体预标记的DC现在可以用于非侵入性地确定治疗性DC注射的准确性，初始DC分散，全身DC分布和DC迁移到LN和LN内。磁疫苗接种是一种替代方法，其跟踪体内标记的DC，其同时原位捕获肿瘤抗原和MR造影剂，从而能够准确定量抗原呈递给LN中的T细胞。MRI DC跟踪的最终临床前提是使用LN MRI信号的变化作为早期成像生物标志物，以在治疗结果变得明显之前很久预测肿瘤疫苗接种和抗肿瘤反应的疗效，这可能有助于临床医生进行中期治疗管理。
Cancer vaccination using tumor antigen-primed dendritic cells (DCs) was introduced in the clinic some 25 years ago, but the overall outcome has not lived up to initial expectations. In addition to the complexity of the immune response, there are many factors that determine the efficacy of DC therapy. These include accurate administration of DCs in the target tissue site without unwanted cell dispersion/backflow, sufficient numbers of tumor antigen-primed DCs homing to lymph nodes (LNs), and proper timing of immunoadjuvant administration. To address these uncertainties, proton (1H) and fluorine (19F) magnetic resonance imaging (MRI) tracking of ex vivo pre-labeled DCs can now be used to non-invasively determine the accuracy of therapeutic DC injection, initial DC dispersion, systemic DC distribution, and DC migration to and within LNs. Magnetovaccination is an alternative approach that tracks in vivo labeled DCs that simultaneously capture tumor antigen and MR contrast agent in situ, enabling an accurate quantification of antigen presentation to T cells in LNs. The ultimate clinical premise of MRI DC tracking would be to use changes in LN MRI signal as an early imaging biomarker to predict the efficacy of tumor vaccination and anti-tumor response long before treatment outcome becomes apparent, which may aid clinicians with interim treatment management.
登录
查看更多内容
影响因子：
3.7
作者：
Ferguson PM;Slocombe A;Tilley RD;Hermans IF
通讯作者：
Hermans IF
影响因子：
82.9
作者：
Figdor, CG;de Vries, IJM;Melief, CJM
通讯作者：
Melief, CJM
影响因子：
46.9
作者：
Ahrens, ET;Flores, R;Morel, PA
通讯作者：
Morel, PA
影响因子：
5.5
作者：
Baldwin, Susan L.;Shaverdian, Narek;Reed, Steven G.
通讯作者：
Reed, Steven G.
影响因子：
5.4
作者：
Baumjohann, Dirk;Hess, Andreas;Lutz, Manfred B.
通讯作者：
Lutz, Manfred B.